Levetiracetam Stragen

Levetiracetam, the active ingredient in Levetiracetam Stragen, is an anticonvulsant presented as an intravenous solution for intravenous use. It is indicated for the treatment of partial onset seizures, generalized tonic‑clonic seizures and myoclonic seizures, providing rapid control of seizure activity in hospitalised patients and those requiring acute intervention.

GNH USA supplies Levetiracetam Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution across regulatory‑compliant channels.

Levetiracetam is used in the management of epileptic seizure disorders, targeting various seizure types. - Partial onset seizures: reduces frequency and severity of focal seizures. - Generalized tonic‑clonic seizures: helps achieve seizure control in patients with convulsive episodes. - Myoclonic seizures: diminishes rapid jerking movements associated with myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling of tiredness or reduced energy. - Headache: mild to moderate cranial pain. - Irritability: mood changes including agitation or nervousness.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention. - Mood or behavioral changes: depression, suicidal thoughts, or aggressive behavior. - Blood disorders: thrombocytopenia or neutropenia, indicated by abnormal blood counts.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dosing or monitor renal function in patients with reduced kidney clearance. - Hepatic dysfunction: evaluate liver status as metabolism may be altered. - Psychiatric history: monitor for new or worsening mood disturbances. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy and lactation: lack of comprehensive data; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control. - Phenobarbital: can lower levetiracetam concentrations, risking breakthrough seizures.

Moderate Interactions (Monitor Closely): - Sedative agents (e.g., benzodiazepines, opioids): may enhance central nervous system depression. - Antidepressants (e.g., SSRIs): monitor for increased irritability or mood changes. - Immunosuppressants (e.g., cyclosporine): observe for potential alterations in drug levels.